Indoco Remedies Allots 55,700 Equity Shares Under Employee Stock Option Plan

Indoco Remedies Limited has completed the allotment of 55,700 equity shares under its Employee Stock Option Plan-2022, marking a significant step in its employee compensation strategy. The pharmaceutical company announced this development through a regulatory filing dated February 3, 2026. Committee Approval and Meeting Details The Nomination and Remuneration Committee of Indoco Remedies approved the share allotment during its meeting held on February 3, 2026. The committee meeting commenced at 09:00 a.m. and concluded at 09:30 a.m., demonstrating efficient decision-making processes. Share Allotment Breakdown The allotment involves two distinct categories of shares with different pricing structures: Share Category Number of Shares Issue Price (Rs.) Total Value (Rs.) Category 1 42,300 307 1,29,86,100 Category 2 13,400 2 26,800 Total 55,700 - 1,30,12,900 The shares have been allotted to the Indoco Employees Welfare Trust, which will subsequently allocate or transfer these shares to eligible employees upon exercise of their stock options and Restricted Stock Units (RSUs). Impact on Share Capital The allotment has resulted in an increase in the company's paid-up capital structure: Parameter Before Allotment After Allotment Paid-up Capital Rs. 18,44,95,810 Rs. 18,46,07,210 Number of Equity Shares 9,22,47,905 9,23,03,605 Face Value per Share Rs. 2 Rs. 2 Regulatory Compliance The company has fulfilled its disclosure obligations under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The announcement also complies with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, ensuring complete regulatory adherence. ESOP Structure Details The Employee Stock Option Plan-2022 represents Indoco Remedies' commitment to employee participation in the company's growth. The allotted shares will be held by the ESOP Trust until eligible employees exercise their options, providing a structured mechanism for employee equity participation. The significant difference in exercise prices between the two categories reflects different grant terms within the comprehensive ESOP framework. Indoco Remedies has achieved a significant regulatory milestone with the receipt of final approval from the United States Food and Drug Administration (USFDA) for its Lacosamide Oral Solution, 10 mg/ml. This approval enables the pharmaceutical company to manufacture and commercialize a generic version of Vimpat Oral Solution, 10 mg/ml, in the competitive US market. Regulatory Approval Details The USFDA final approval grants Indoco Remedies the authorization to launch its generic formulation of Lacosamide Oral Solution with a concentration of 10 mg/ml. This generic product will serve as an alternative to the branded Vimpat Oral Solution, 10 mg/ml, potentially offering cost-effective treatment options for patients. Parameter: Details Product: Lacosamide Oral Solution Concentration: 10 mg/ml Regulatory Status: USFDA Final Approval Reference Product: Vimpat Oral Solution, 10 mg/ml Market: United States Market Implications The approval strengthens Indoco Remedies' presence in the US pharmaceutical market and adds to its generic drug portfolio. Lacosamide is typically used as an antiepileptic medication, and the availability of a generic version may provide healthcare providers and patients with additional treatment options. Strategic Significance This USFDA approval represents an important development for Indoco Remedies' international expansion strategy. The company's ability to secure regulatory clearance for generic formulations in the US market demonstrates its manufacturing capabilities and regulatory compliance standards. The approval allows the company to participate in the generic pharmaceutical segment for this specific therapeutic area. We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better. Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians. As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.